Young Chang Lim1, Lihua Liu2, Jae Won Chang3, Bon Seok Koo4. 1. Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea. 2. Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, Republic of Korea. 3. Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for Medical Sciences, Chungnam National University College of Medicine, Daejeon, Republic of Korea. 4. Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for Medical Sciences, Chungnam National University College of Medicine, Daejeon, Republic of Korea. Electronic address: bskoo515@cnuh.co.kr.
Abstract
BACKGROUND: This study analyzed the incidence, pattern, and predictive factors for lateral lymph node (LN) recurrence in patients with papillary thyroid cancer (PTC) without clinical evidence of lateral LN metastasis. METHODS: A retrospective analysis was performed on 246 patients with PTC who underwent total thyroidectomy and central neck dissection from 2004 to 2010. None of the patients had clinical evidence of lateral LN metastasis at the time of diagnosis. Predictive factors for lateral LN recurrence were evaluated using the chi-square test. Binary logistic regression was used for the multivariate analysis. Recurrence-free survival rates were estimated by the Kaplan-Meier and Cox regression methods. RESULTS: Of the 246 patients, 11 (4.5%) developed lateral LN recurrence with a median follow-up of 49months. In the multivariate analysis, tumor size >1cm (odds ratio [OR], 8.14; 95% confidence interval [CI], 1.01-65.68; p=0.049) and central LN metastasis (OR, 10.59; 95% CI, 1.32-85.17; p=0.026) were independent predictive factors of lateral LN recurrence. Especially, extranodal extension of a metastatic central LN (OR, 38.82; 95% CI, 5.71-264.10; p<0.001) was an independent predictor of lateral LN recurrence. CONCLUSIONS: Tumor size and central LN metastasis were independent predictors of lateral LN recurrence in patients with PTC without initial clinical lateral neck metastasis who underwent total thyroidectomy and central neck dissection. Close surveillance may be necessary for early detection of lateral LN recurrence in PTC patients with tumor size ⩾1cm, and central LN metastasis with extranodal extension.
BACKGROUND: This study analyzed the incidence, pattern, and predictive factors for lateral lymph node (LN) recurrence in patients with papillary thyroid cancer (PTC) without clinical evidence of lateral LN metastasis. METHODS: A retrospective analysis was performed on 246 patients with PTC who underwent total thyroidectomy and central neck dissection from 2004 to 2010. None of the patients had clinical evidence of lateral LN metastasis at the time of diagnosis. Predictive factors for lateral LN recurrence were evaluated using the chi-square test. Binary logistic regression was used for the multivariate analysis. Recurrence-free survival rates were estimated by the Kaplan-Meier and Cox regression methods. RESULTS: Of the 246 patients, 11 (4.5%) developed lateral LN recurrence with a median follow-up of 49months. In the multivariate analysis, tumor size >1cm (odds ratio [OR], 8.14; 95% confidence interval [CI], 1.01-65.68; p=0.049) and central LN metastasis (OR, 10.59; 95% CI, 1.32-85.17; p=0.026) were independent predictive factors of lateral LN recurrence. Especially, extranodal extension of a metastatic central LN (OR, 38.82; 95% CI, 5.71-264.10; p<0.001) was an independent predictor of lateral LN recurrence. CONCLUSIONS:Tumor size and central LN metastasis were independent predictors of lateral LN recurrence in patients with PTC without initial clinical lateral neck metastasis who underwent total thyroidectomy and central neck dissection. Close surveillance may be necessary for early detection of lateral LN recurrence in PTC patients with tumor size ⩾1cm, and central LN metastasis with extranodal extension.
Authors: Suvi Renkonen; Riikka Lindén; Leif Bäck; Robert Silén; Hanna Mäenpää; Laura Tapiovaara; Katri Aro Journal: Eur Arch Otorhinolaryngol Date: 2017-09-02 Impact factor: 2.503